A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis

Hand Dermatitis Clinical Trial

— AFX5931  

Official title:

"A Double-Blind, Pilot Study to Evaluate the Efficacy and Safety of Topical AFX 5931 in the Treatment of Mild to Moderate Hand Dermatitis"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03703895
• Other study ID #: CCCR 08-2018
• Secondary ID: AFX5931-A 073120
• Status: Completed
• Phase: Phase 4
• Start date: September 18, 2018
• Est. completion date: April 4, 2019

Study information

• Verified date: December 2022
• Source: The Center for Clinical and Cosmetic Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the study. Subjects will be randomized in a 3:1 ratio to receive either the active or vehicle medication. 15 subjects will receive the active, therapeutic product and 5 subjects will receive the inactive, vehicle product.

Description:

This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the study. Subjects will be randomized in a 3:1 ratio to receive either the active or vehicle medication. 15 subjects will receive the active, therapeutic product and 5 subjects will receive the inactive, vehicle product. Subjects will complete 4 study visits according to the following 4-week timeline: Day [-30] - [-1] (Screening), Day 0 (Baseline), Day 14 (Follow-Up), Day 28 (Follow-up | ET | EOS). At Visit 2, IP will be dispensed and baseline readings of efficacy as well as safety/tolerability assessments will be obtained prior to application of the IP. Subjects will apply IP twice daily and compliance will be monitored by periodically reviewing the subject diary. The evaluations that will be used to measure efficacy of the product will be the Investigator's Global Assessment and Hand Eczema Severity Index. The Subject's Local Dermal Tolerability Assessment and Local Skin Reaction Assessment will be used throughout the course of the study to evaluate tolerability. Additionally, the actions that will be taken to evaluate safety will be the monitoring of adverse events, vital signs, and changes in concomitant medications. Digital photographs will be taken at each visit (excluding Visit 3).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 4, 2019
• Est. primary completion date: April 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Subject is a male or non-pregnant female, 12 years of age and older.

2. Subject is willing and able to provide written informed consent for the study.

3. Subject is willing and able to apply the investigational product as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.

4. Subject has clinical diagnosis of mild to moderate hand dermatitis for at least 3 months.

5. Subject has a baseline Investigator's Global Assessment (IGA) score of 2 or 3 (disease severity of mild or moderate).

6. Subject is in good general health and free of any disease state or physical condition that might impair evaluation of hand dermatitis or which, in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.

7. Women of childbearing potential (WOCBP) must use an effective method of birth control or must be post-menopausal or surgically sterile. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Baseline.

Exclusion Criteria:

1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

2. Subject is currently enrolled in an investigational drug or device study.

3. Subject has used an investigational drug or investigational device treatment within 30 days prior to Visit 2/Baseline.

4. Subject has active cutaneous bacterial or viral infection in any treatment area (clinically infected hand dermatitis) at Visit 2/Baseline.

5. Subject has used any of the following therapies within 30 days prior to Visit 2/Baseline:

• Systemic corticosteroids (oral and injectable [intravenous and intramuscular]) (Intranasal and Inhalational steroids are allowed if use is kept constant during the study)

• UVA/UVB therapy

• PUVA (psoralen plus ultraviolet A) therapy

• Immunomodulators or immunosuppressive therapies

• Interferon

• Cytotoxic drugs (e.g., methotrexate, cyclophosphamide, azathioprine)

• Oral retinoids

6. Subject has used any of the following therapies within 14 days prior to Visit 2/Baseline:

• Systemic antibiotics

• Topical calcipotriene or other topical vitamin D preparations

7. Subject has used any of the following therapies within 7 days prior to Visit 2/Baseline: • Topical and oral antihistamines

• Topical antibiotics

• Topical corticosteroids

• Topical antifungals

8. Subject has a history of sensitivity to any of the ingredients in the investigational product

9. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

Related Conditions & MeSH terms

• Dermatitis
• Hand Dermatitis

Intervention

Drug:
• Topical AFX5931
Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
• Topical Placebo
Placebo Comparator, Topical Placebo.

Locations

Country	Name	City	State
United States	The Center for Clinical and Cosmetic Research	Aventura	Florida

Sponsors (2)

Lead Sponsor	Collaborator
The Center for Clinical and Cosmetic Research	Afecta Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome Measure for Efficacy (IGA)	To measure the efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis in subjects 12 years of age or older assessed via the Investigator's Global Assessment; The investigator will rate the subject's hand dermatitis on a visual 5-point scale as follows: 0: Clear: No signs of HE; Almost clear: Just perceptible scaling and/or erythema; Mild disease: Mild scaling and/or mild erythema, and/or mild cracking; Moderate disease: Moderate scaling and/or erythema, and/or moderate cracking/fissuring; Severe disease: Severe scaling and/or severe erythema, and/or severe cracking/fissuring; Dorsal and palmar surfaces of the hand are evaluated together.	Baseline; Day 14; Day 28
Primary	Primary Outcome Measure for Efficacy (HECSI)	To measure the efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis in subjects 12 years of age or older, assessed via the Hand Eczema Severity Index (HECSI).; Investigator-rated clinical evaluation; Locations: fingertips, fingers (excluding tips), palms of hands, backs of hands, wrists; Intensity: graded on a visual 4-point scale (0 = no skin changes, 1 = mild disease, 2 = moderate, 3 = severe) for each Clinical sign (erythema, infiltration/papulation, vesicles, figures, scaling, and edema) at each location.; Extent: graded on a visual 5-point scale (0 = 0% ; 1 = 1-25% ; 2 = 26-50% ; 3 = 51-75% ; 4 = 76-100%) for each location.; Total HECSI score (0 to a maximum severity score of 360): the sum of the Intensity of clinical signs multiplied by the Extent grade for each location. The sum of the location scores is the Total HECSI score.	Baseline; Day 14; Day 28
Secondary	Secondary Outcome Measures for Tolerability and Safety (Tolerability Assessment - Pruritus Score)	The subjects will be asked to grade their feeling of itching at the application site using a 4-point tolerability scale, where 0=None, 1= Mild, 2= Moderate, and 3=Severe.; Pruritus: Definition: itching 0 = None: No itching; = Mild: Occasional, slight itching/scratching; = Moderate: Constant or intermittent itching/scratching/discomfort that is not disturbing sleep; = Severe: Bothersome itching/scratching/discomfort that is disturbing sleep	Baseline; Day 14; Day 28
Secondary	Secondary Outcome Measures for Tolerability and Safety (LSR)	The investigator/ designee will describe their Local Skin Reaction (LSR) assessment of the subject's hands using a 4-point tolerability scale.; Erythema: abnormal redness of the skin 0 = No erythema; = Mild (Slight pinkness present); = Moderate (Definite, dull redness that is clearly distinguishable); = Severe (Intense, deep redness); Induration/Papulation: inflammation, swelling 0 = No elevation; = Mild (Slightly perceptible elevation); = Moderate (Clearly perceptible elevation but not extensive); = Severe (Marked and extensive elevation); Lichenification: thickening upper layers of skin 0 = No thickening; = Mild (Slight thickening of skin discernible only by touch and with skin markings minimally exaggerated); = Moderate (Definite thickening of the skin with skin markings exaggerated so that they form a visible crisscross pattern); = Severe (Thickened, indurated skin with skin markings visibly portraying an exaggerated crisscross pattern)	Baseline; Day 14; Day 28
Secondary	Measures for Safety (Adverse Events/Concomitant Medications)	Monitoring the record of AEs (Adverse Events) and changes in concomitant medication/ procedures throughout the course of the study will be the primary mode of safety evaluation.; At each level of summarization (global, body system, and preferred term), a subject will be counted once if they reported one or more AEs at that level.; No statistical testing will be performed.	Baseline; Day 14; Day 28

External Links

•   Afecta Pharmaceuticals